NOXXON TO HOST KEY OPINION LEADER WEBINAR ON GLORIA STUDY TOP-LINE RESULTS OF NOX-A12 & RADIOTHERAPY COMBINATION IN FIRST-LINE GLIOBLASTOMA

Berlin, Germany - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that it will host a key opinion leader (KOL) webinar on the top-line results of GLORIA on Friday, June 10, 2022, at 2:00 p.m. CEST / 08:00 a.m. EDT. GLORIA is a Phase 1/2 study of NOX-A12 and radiotherapy combination in first-line glioblastoma multiforme. The top-line data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

The webinar will feature a presentation from Frank A. Giordano, M.D., Chair, Department of Radiation Oncology, University Hospital Bonn, Germany, who will present and discuss the results of the GLORIA Phase 1/2 trial evaluating NOX-A12 in combination with radiotherapy in patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. The webinar will follow Dr. Giordano's poster presentation at the 2022 ASCO Annual Meeting that will take place from June 3-7, 2022, in Chicago, Illinois, United States. Dr. Giordano will discuss the results based on 6-month therapy of patients treated in the GLORIA study that complement the recently reported positive data.

NOX-A12 is an inhibitor of the chemokine CXCL12 and has been granted orphan drug status in the US and EU for the treatment of certain brain cancers and produced promising clinical data thus far. Dr. Giordano will be available for questions following the formal presentation.

LifeSci Advisors Guillaume van Renterghem Tel. [phone] [e-mail]

About NOXXON

NOXXON's oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON's approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON's lead program NOX-A12 has delivered final top-line data from a Keytruda combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda and two different chemotherapy regimens as secondline therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has delivered top-line data from all three dose-escalation cohorts showing consistent tumor reductions and objective tumor responses. Additionally, GLORIA has been expanded to assess the benefit of NOX-A12 with other treatment combinations, radiotherapy + bevacizumab and radiotherapy + pembrolizumab. The company's second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. Further information can be found at: www.noxxon.com.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

(C) 2022 Electronic News Publishing, source ENP Newswire